NAV
$46.17
AUM
$105.1M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.00
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +26.01% | +21.76% | +31.18% | +85.82% | - | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | TVTX | Travere Therapeutics Inc Ordinary Shares | 7.67% |
| 2 | COGT | Cogent Biosciences Inc | 7.53% |
| 3 | LIVN | LivaNova PLC | 7.11% |
| 4 | SYRE | Spyre Therapeutics Inc | 6.41% |
| 5 | GH | Guardant Health Inc | 5.52% |
| 6 | MIRM | Mirum Pharmaceuticals Inc | 4.92% |
| 7 | CORT | Corcept Therapeutics Inc | 4.79% |
| 8 | UTHR | United Therapeutics Corp | 4.16% |
| 9 | MANE | Veradermics Inc | 3.42% |
| 10 | SVRA | Savara Inc | 3.22% |
The fund is an actively managed exchange-traded fund (“ETF”) and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund’s investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.
Inception Date: 2024-10-30